https://sentynl.com/privacy/
Privacy - Sentynl Therapeutics, Inc.
Sentynl Privacy Statement Effective Date: May 18, 2020 Updated Date: March 11, 2025 Sentynl Therapeutics, Inc. (“Sentynl,” “We” or “Our”) are committed to...
sentynl therapeuticsprivacyinc
https://sentynl.com/contact/
Contact - Sentynl Therapeutics, Inc.
Contact We Look Forward to Connecting With You For business development, please visit our Business Development page. To report an adverse event or product...
sentynl therapeuticsinc
https://sentynl.com/terms-of-use/
Terms of Use - Sentynl Therapeutics, Inc.
Terms of Use Effective: November 23, 2015 Updated Date: November 6, 2023 This Terms of Use Agreement and our Privacy Statement (together, these “Terms”)...
sentynl therapeuticstermsuseinc
https://sentynl.com/
Home - Sentynl Therapeutics, Inc.
Sentynl Therapeutics, Inc. is a US-based specialty pharmaceutical company dedicated to improving patient care through innovative therapeutics.
sentynl therapeuticsinc
https://aboutmocdtypea.com/
About MoCD Type A | Rare Disease Education By Sentynl Therapeutics, Inc.
MoCD Type A is a treatable disease that often appears in the first weeks of life with seizures | Info by Sentynl Therapeutics, Inc.
rare diseasesentynl therapeuticstypeeducationinc
https://sentynl.com/accessibility/
Accessibility - Sentynl Therapeutics, Inc.
Sentynl Therapeutics, Inc. Accessibility Statement Updated: December 2022 General Sentynl Therapeutics, Inc. strives to make its websites accessible to people...
sentynl therapeuticsaccessibilityinc
https://sentynl.com/about-us/
About Us - Sentynl Therapeutics, Inc.
Focused on Rare Disease Our Guiding Principles Our goal is to provide novel biopharmaceutical medicines that extend, improve, or enhance the lives of people...
sentynl therapeuticsusinc